Parameter
| Biomarker | APOE ε4 | Full name | Apolipoprotein Eε4 allele | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Susceptibility | ||
| Disease | Liver Cirrhosis | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Whole blood (genotyping) | ||
| Pathobiological Mechanisms | Influence of lipid metabolism, especially related to cleared A beta efficiency is lower, carried A beta risk and time in advance. | ||||
| Clinical Availability Status | Clinical available (risk assessment) : conventional genetic tests available, but only for risk assessment, is not used for diagnosis. Important ethical issues are involved. | ||||
| Notes and Dynamics | It is the core variable of establishing risk stratification model; It is also an important stratification factor in treatment trials. | ||||